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In the September issue of this newsletter, we printed the following : 
"Volunteers are needed for a special Aids vaccine program. You 
must have a negative HIV antibodies test reading to qualify . 
The program will be held in Bethesda, Maryland with travel ex-
penses paid. Please call 301-496-7196 for further information . " 
Well, before the newsletter even hit the mails, I had called that 
number , and was on my way to being a volunteer for the program. I knew 
immediately that I had to do this, or at least try. I finally made an 
appointment for October 21st for the initial examination. The program 
is conducted at The National Institutes of Health in Bethesda, Maryland . 
It is technically called "A toxicity/immunogenicity study of a re-
combinant HIV-envelope protein (gpl60)." This manufactured protein is 
identical to the outer coating of the Aids virus . However , i t contains 
no live or killed virus, so you will not get Aids. 
I was no t ified in early December that I passed my initial exam with 
fl y ing colors, so to speak . I returned to Bethesda on December 29t h 
and 30th for a complete physical exam plus more blood work, and an 
extensive question and answer period. After indicating my desire to 
continue on with the program, I was given the vaccine!!!!! I was g : ·- ~n 
20ug (units) of gpl60 by injection in the upper arm muscle. I wi ll ~ 2-
turn to Bethesda once a week for the next four weeks for blood work and 
observation. On the fourth week, I will be given a booster shot of 20ug 
units more of gpl60. I will then return to Bethesda once a month for 
one year. I will periodically give a progress report in this newsletter . 
In the meantime, they are still in need of more volunteers for this 
program. If you are interested in paricipating in this fantastic op-
portunity, please call Margaret Megill, R.N. or Victoria Davey, R . N. at 
301-496-7196. I would also be happy to relate any information I can to 
interested parties - call me (David Ketchum) at 934-4997 - leave a 
message, and I will return all calls . 
I have nothing but praise for the staff at The National Institutes of 
Health. Their dedication , concern, and caring is quite obvious. It is an 
uplifting experience that I feel very positive about. It may not be a 
cure, but it is certainly a step in the right directjon. We must have 
HOPE. Please volunteer NOW . 
HUGGING 
(THE MIRACLE DRUG) 
* IT HELPS THE BODY'S IMMUNE SYSTEM *IT KEEPS YOU HEALTHIER *IT CURES 
DEPRESSION *IT REDUCES STRESS *IT INDUCES SLEEP *IT'S INVIGORATING 
*IT'S REJUVENATING *IT HAS NO UNPLEASANT SIDE EFFECTS .. .. .. . 
I 
PWA COALITION 
I am appealing to every PWA, persons with ARC and HIV positive to please 
step forward and assist me in forming a PWA coalition in Maine. 
I have been a board member of the Maine Health Foundation, worked on joint 
ventures with the AIDS Project and listened to a great deal of dialogue of what 
is best and can be done for PWAs, persons with ARC and HIV positive. I have been 
to Washington and other political activities and also listened. Although very 
well intentioned by a body of wonderfully concerned individuals with alot of 
love and compassion, who knows better of the needs of this population than the 
"silent population" itself? I feel we can better voice our needs, concerns, 
and offer a support system that is unsurpassed by any other present group. I 
feel we are a group who needs to empower ourselves to help ourselves in various 
aspects. 
I am not asking anyone to break their anonymity, become politically 
active or join any present program. I'm asking for people to get together to 
dialogue needs, concerns and how they can best be met. Needs may vary and 
be as simple as to get together with other people with a COITJllOn disease who 
understand and dialogue in an informal setting. I have seen this work in other 
cormrunities and work well. We have brothers and sisters not getting the 
assistance they desperately need for various reasons, let's give them or us 
that "safe" place to come together. A place that is not connected to any 
program but is an entity unto itself, to help individuals they understand due 
to being part of that population. A place to have a united and consistent 
voice. 
A new year is approaching, let's get together, discuss our needs and con-
cerns in the upcoming year and get to know one another. Society at large wishes 
to keep us silent and in our "closets", let's not feed into this and do it our-
selves. 
On a personal note, I wish to meet others in my situation to come together 
.I 
and•think there are others out there who feel the same. 
Please contact me, Bert, at 775-1259, or Zane or Vincent if you have 
any questions, camients and/or interest. 
We need your help. 
Anonymity assured. 
*EDITOR'S NOTE: Persons interested in the formation of a PWA Coalition 
in Maine, can also contact David Ketchun at 934- 4997. Bert will be in 
New York during the b~;inning of January, therefore, I will pass on 
all pertinent information to him when he returns . 
From The Office on AIDS 
The Community AIDS Education Project 
Over the past year, interest in AIDS and the need for local AIDS 
education and information programs have dramatically increased. In 
response, many local com~unities throughout Maine have developed AIDS 
education and support services. Many of these conrnunity-based groups are 
beginning to feel the overwhelming pressure of providing AIDS education to 
religious groups, civic organizations, local businesses, professionals, 
schools, townspeople, social services agencies, health care institutions, 
etc. 
Some groups have discovered that, even in small communities, it's very 
difficult to provide AIDS education with limited financial and human 
resources. For groups that are staffed by volunteers, there are problems 
finding the time and energy to accomplish basic tasks. The expenses 
associated with obtaining and distributing brochures; publicizing meetings 
and conferences; and phone, postage, and travel are also limiting the 
activities of these groups. 
In order to begin addressing these concerns, the state legislature has 
appropriated funds to help promote AIDS education efforts at the conrnunity 
level. The Office on AIDS will be spearheading this project and is actively 
seeking comments from a 11 communitj-based organizations who are offering 
AIDS education. Our initial plans include locating your groups and 
identifying the areas in Maine where AIDS education is not being addressed, 
sponsoring a statewide "get-acquainted" meeting of representatives of your 
groups, and conducting a needs assessment to establish how to best apply our 
limited funds to this seemingly limitless project. For more information, or 
to express your interest in th is project, please contact Peaches Bass, 
Office on AIDS, State House Station 11, Augusta, 04333, 289-3747. 
AIDS Conference 
Documentary 
Through the help of a $6400 grant from Blue 
Cross/Blue Shield of Maine, the MHC will be able 
ro make a one hour video documentary of its confer· 
ence, "AIDS: Plague, Panic and the Test of Human 
Values," which took place this May at the Augusta 
Civic Center. Held before an audience of over 500 
concerned citizens, the aim of the conference was to 
examine our responses to AIDS in light of the his-
tory of other epidemic diseases and the patterns of 
social, sexual, and cultural conflict that they 
produced. 
Keynoted by Susan Sontag, the day featured pre· 
sentations by medievalist David Herlihy of Brown, 
social historian of medicine Allan Brandt of Har· 
vard, and theologian Tom Driver of the Union 
Theological Seminary; Maine scholars from Bow-
doin and the University of Maine conducted 
workshops on philosophical, literary, and artistic 
representations of disease in Europe and America . 
The dav ended with a series of hard quesnons for 
. those c~rrently shaping public policy about AIDS in 
Maine. Using excerpts from all of these talks, the 
Council hopes to capture in this video the dominant 
sense of the conference: that human reason and 
discourse can generate hope even in the face of hor· 
rifying and real threats to life. The video will be 
available from the Council. 
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LET'S HUG 
THERE'S A HUG TO SAY 
I LOVE YOU 
AND A HUG TO SAY GOODBYE 
THERE'S A HUG TO SAY 
HOW ARE YOU 
AND A HUG TO SAY, WE TRIED 
THERE'S A HUG TO BOND 
A FRIENDSHIP 
AND A HUG WHEN THE DAY 
IS THROUGH 
BUT THE HUG I LOVE 
IN ALL THE WORLD IS 
THE HUG I GET FROM 
YOU! 
The following article is part two in a series of related subjects con-
cerning various drugs used for the treatment of AIDS . It is reprinted wi th 
permission from the PWA Coalition of New York City . 
ACYCLOVIR 
by R. C. Morse 
Acyclovir, or ACV, is an antiviral that was initially developed for treatment of herpes 
simplex. It is manufactured under the brand name Zovirax by Burroughs Wellcome. Its anti-
viral action became of interest to AIDS researchers at the National Cancer Institute (NCI) 
in Bethesda, Maryland, where it was postulated from cell culture studies that ACV might 
work synergisticly with AZT. 
An NCI phase one trial began in December 1986 and ended in July 1987 (results are ex-
pected to be published this fall in a medical journal) . Eight individuals with symptoms 
ranging from ARC to AIDS (KS/PCP) were treated with both AZT and ACV. AZT was administered 
at slightly lower dosages than the regimen calls for to lessen its side effects and toxicity . 
By administering the two antivirals simultaneously, NCI researchers are attempting to derive 
empirical evidence that AZT works better in blocking HIV in tandem with ACV. 
Other similar trials are being conducted under the auspices of the National Institute 
of Allergy & Infectious Diseases (NIAID), also in Bethesda. Of all government agencies, 
NIAID seems to be taking the most aggressive approach to AIDS research . NIAID has estab-
lished or is establishing Clinical Studies Groups, National Drug Discovery Groups, National 
Cooperat i ve Vaccine Development Groups, Vaccine Evaluation Units, AIDS Treatment & Evaluation 
Units (ATEUs), as well as a national computerized genetic database for use by medical 
professionals. 
Some 19 ATEUs were established in 1986 in 11 states, affiliated with some 35 leading 
medical and university research centers. As of July 31st, there were 20 active studies 
with 1,072 individuals participating at 16 of the centers. Also by the end of July, in 
addition to ACV , ATEUs were also evaluating six other AIDS-related drugs. (NIAID is also 
planning a trial for ribavirin, as well as a phase one study for AL-721.) 
One of the ATEUs is specifically testing a protocol including both AZT and ACV . This 
placebo controlled trial is evaluating the pharmacokinetics and pharmacodynamics of AZT and 
ACV when administered concomitantly. Individuals are divided into six distinct groups : 
a ) gets a small dose of AZT and no ACV, while b ) gets the same small dose of AZT, but with 
800 mg. of ACV; c) do the same with larger doses of AZT ; and e ) and f) the same with regi-
men levels of AZT. As of the end of July , nine individuals were enrolled in what is ex-
pected to be a 12-week study. Once toxicity levels are established, the trial will attempt 
to determine if achievable concentration of AZT and ACV have a synergistic activity against 
HIV infection. 
AMPLIGEN 
Ampligen was developed by HEM Research, Inc . of Rockville, MD. HEM is a privately 
held company formed in 1966 to analyze and develop mammalian cell culture and growth media. 
It later developed compounds to stimulate or amplify the immune system. HEM was the first 
company to commercially produce beta interferon. 
Its newest product, Ampligen, is a patented, mismatched, double stranded RNA molecule 
that may be a therapeutic antiviral for HIV+/ARC/AIDS. The first in vitro trial (an inde-
pendent study by HEM) ran in 1986 through early 1987 with 10 individuals at George Washington 
University and Hahnemann University. The results proved impressive. 
In a nutshell , Ampligen may prove to be more powerful than AZT, with no toxic side ef-
fects, and may also help to increase the all-critical T4 cell count. According to the study's 
authors, their report published in "The Lancet" on June 6th states: Ampligen seems to have 
the dual ability to restore immunological functin and to control HIV replication." 
Inside an individual's body, Ampligen acts like an artificial virus. The immune system 
recognizes Ampligen not as an artifical agent, however, but as the real thing. This subse-
quently stimulates the body's own natural interferon production. Interferon, in turn, 
stimulates the growth and development of healthy red and white blood cells. Ampligen has 
also been demonstrated to inhibit HIV virus replication . 
The 10 individuals in the study covered the range of infection from ARC to KS/PCP . 
They r eceived 200- 250 mg. of Ampligen intravenously twice a week for the duration. According 
to results published in "The Lancet", no side effects or toxicity were observed in any of the 
individuals involved . After 2-8 doses, seven subjects reported increased energy levels , im-
proved performance status, and lymph node shrinkage. In individuals that were removed from 
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treatment after more than a dozen doses, symptoms did not appear again for 2-3 weeks, but 
then fatigue and other symptoms began reappearing. When treatment was resumed, the symptoms 
again abated. 
As an antiviral, Ampligen showed a significant effect in reduction of HIV expression in 
9 of the 10 individuals involved in the study, with greatest changes occurring in individuals 
with ARC. Acting as a well-tolerated antiviral, Ampligen also seems to have potential as an 
immune system modulator. In those individuals with ARC, T4/T8 white cell ratios improved in 
as soon as 2-4 weeks of treatment. In those individuals with full-blown AIDS, a 2-5 fold in-
crease in T4 cells occurred at 4 weeks. In total, T4 cell counts rose in 8 of the 10 indi-
viduals enrolled in the study. 
The authors of the report suggest that Ampligen may have two theoretical advantages 
over AZT : no side effects or toxicity. The authors also suggest that Ampligen may be most 
efficacious in the early stages of HIV infection, rather than at the state of full-blown 
AIDS. They also believe it may work synergisticly with AZT, so that a combination of the 
two (with lower, less toxic doses of AZT) may act better on those individuals with fully de-
veloped AIDS. Ampligen is also believed to have the ability to cross the blood-brain barrier 
treatment AIDS-related neurological disorders. 
The potential seen from this preliminary study was enough for Delaware-based DuPont to 
acquire a minority equity position in HEM, an action that was announced on May 28th. With 
DuPont's manufacturing and clinical capabilities, as well as its previous experience in de-
velopment and marketing AIDS diagnostics, Ampligen is now being tested further. A clinical 
trial with some 200 individuals participating began this summer in New York, Philadelphia, 
and Washington, D.C. This is a double-blind, placebo-controlled study. At this time, there 
are no plans to test Ampligen concomitantly with AZT. Results from this phase two trial are 
expected to be released by the end of the year once the data have been collected and analyzed. 
AN ALBUM BY 
ARNE HANSON 
FEATURING 
DEVONSQUARE/MARY HANSON AND A COL-
LECTION OF MAINE'S FINEST MUSICIANS. 
WHEN YOU BUY THIS ALBUM. -----a 
------PARTIAL PROCEEDS WILL GO 
TO THE AIDS PROJECT WITH ITS AZT SUPPORT 
PROGRAM AND SUPPORT SERVICES FOR AIDS 
PATIENTS AND THEIR FAMILIES. 
ALBUM OR CASSETIE TAPE $8.98 
SEND $8.98 PLUS $1.00 SHIPPING 
& HANDLING TO : 
THE AIDS PROJECT 
"RECORD" 
48 DEERING ST. 
PORTLAND, ME 04101 
FOR FURTHER INFORMATION CALL: 
(207) 774-~$'7'7 
TRIBUTE TO MICHAEL HANSEN 
by Tom Cunningham 
Michael Hansen died of AIDS on June 27th at age 31. 
Michael was a gifted actor, singer/songwriter, and 
teacher, who touched all that he met with warm, 
unconditional love. He will be remembered by this 
love, his humor, his beauty, and his music. He 
will be missed by many forever. The following is 
a song of love and great hope he wrote and re-
corded after his diagnosis: 
WE'VE GOT TODAY 
We got problems, kid 
and the rent is barely paid 
They turned the phone off 
my bal is never made 
They're talking deadlines 
they're talking hard times ahead 
They're printing headlines 
that keep the fatalistics fed 
They're cutting lifelines instead 
But we -'ve got today 
no matter what they say, we've got today 
and that's time enough to say 
how much you mean to me 
Pastures are green to me 
when I know you care 
There's so many would've run 
there's so many would condemn 
but here you are 
just loving me again 
We're sharing secrets 
we're laughing harder than we did 
We're staying up late 
acting like we're kids 
We're trading teardrops we've hid • •. 
So it's love over everything 
with laughter as my friend 
My tears are crystals 
that help me start again 
It's a teddy bear to take the place 
of dragons that I slay 
It's a light that shines so simply 
even if it's night or day 
We've got today 
No matter what they say, we've got today 
and that's time enough to say 
how much you mean to me 
pastures are green to me 
when I know you care 
We've got today .•• 
(Copywright 1986 by Michael Hansen) 
Reprinted with permission 
from the PWA Coalition 
of New York City. 
-
"I'm sorry , s,r, but tlHS survey does nol allo w 
for lhal opinion ." 
-
-
D!HECTLY SPEAKING 
by 
Gary L. Anderson 
It was Just about this time 
three years ago that I first became 
active in the AIDS arena. That may 
not seem like a very long time ago, 
but then there was no such thing as 
the AIDS Project . It has taken alot 
of work by alot of dedicated people 
to get us where we are today. 
But the work that needs doing 
has Just begun . The epidemic of HIV 
disease in this state is sti 11 
nascent and it will be years before 
its full impact is felt. Compared 
to the future, these past few years 
have been the easy ones. 
The AIDS ProJect has made many 
contributions in the fight against 
the spreao of HIV disease in Maine 
and in providing support services to 
t~ose Maine people who have HIV 
disease. The AIDS Project has grown 
ano changed along the way. A 
grassroots organization meeting in 
churches and a bookstore has become 
a corporate entity, an agency . And 
it will continue to grow and change 
as the epidemic spreads . 
1988 wi 11 be a hard year for 
the people of Maine. More and more 
people in our lives will be touched 
by HIV disease. The role of the 
AIDS Project wi 11 become ever more 
crucial. 
As the AIDS Project struggles 
to expand and improve the caliber of 
its services, some important changes 
wl 11 take place. We wi 11 count on 
your support during these periods of 
transition. It has been your 
support and encouragement over the 
past three years that has kept us 
going. But, your support will never 
oe neecea more than it wl 11 be in 
the year we ' ve Just begun. So bear 
with us . Or, better yet, help bear 
us along or. our way to becoml ng a 
oetter agency . 
The real work is still ahead. 
SAFER 
SEX 
CAN BE SENSUOUS! 7 
-
Safety Tips for Vacation Trips 
.. . ~ ~ .. 
AIDS Proiect Hosts 
Hol Jday DJnner 
'~ ~i· · 
On Sunday, Dec. 20th, the AIDS 
Project Board of Directors hosted a 
Christmas dinner at Boone's ln Port-
! and. Twenty-one persons with HIV 
disease and their special guests 
were ln attendance. A surprise 
visit from Santina CSanta was busy 
elsewhere> heightened the good will 
and good cheer of the evening. 
Thanks go to Robert Mi tche I 1 , 
Board President, and Lucy Marbach, 
Client Services Coordinator, for 
thier hard work in pulling this off 
Cand Lucy especially for finding all 
the right gifts>. Thanks to Kristen 
Kreamer for her jocular ad-libbing 
performance as Santina. 
SOME THOUGHTS ON AIDS ISSUES 
By Mike Ossias 
I have a few thoughts on AIDS and AZT that might help the newly diagnosed, and figured 
it was about time I wrote something for your Newsline. Credentials first: I presented with 
PCP in November 1985. I'd been ARC for a year or so, but my friendly (ex) GP basically 
fudged, and I was too ignorant and unwilling to look at what was going on to question him 
fully. This leads to my first point. It's really important for you to get as much informa-
tion as possible on not just the major aspects of the disease, but also on all sorts of 
smaller annoyances that can crop up. You can do this in a mammoth library session, or by 
asking other PWAs, and definitely by asking your doctor to explain things. A lot of doctors 
are very casual in their explanations, but it's important to press them. 
Have a dialogue with your doctor. The only way you can do this successfully is to be-
come at least passingly familiar with the pertinent medical terms and with the body's workings. 
We differ in our capacities to absorb medical information, but we can achieve a certain degree 
of medical literacy, especially about AIDS and ARC, and that's vital. I've heard too many 
horror stories in the past two years to believe that all the doctors treating AIDS actually 
know what they're doing. The more you know, the less you might suffer. 
On to AZT. Yeah, another opinion, but based on a lot more experience than most. I par-
ticipated in the Phase II trials that began in April 1986 and led to release of the drug. In 
fact, I was the first person in the New York City trials to get AZT (as opposed to placebo). 
That was in April '86, and I'm still on AZT. I can tell you that it created a significant 
improvement in the quality of my day-to-day existence with AIDS. No, AZT does not prevent 
PCP -- I found that out the hard way. No, AZT has not prevented the emergence of KS in my 
body, though it may have slowed it down. And yes, I've been affected by the toxicity, put 
on half dose, and been given innumerable transfusions (well, at least 15; I've lost count). 
Apparently I had the dubious distinction of being one of the most sensitive in the study to 
the bone marrow suppressive qualities of the drug. So much for negatives. The fact is, AZT 
is doing a lot of good for a lot of people, and I've personally seen some miraculous results 
of going on it. 
That's why I get irritated when people criticize AZT for not doing more. It's not a 
panacea and no one said, ever, that it was a cure. But to refer to it, as Michael Callen did 
recently, as "that poison" is simply irresponsible. Some of us know better, but someone newly 
diagnosed is still feeling his or her way, and deserves not to be terrorized. 
To those trying to decide whether or not to go on AZT, I'd say, try to find out about 
others' actual experience with the drug and weigh the symptoms you hear about against the ac-
knowledged benefits. Transfusions are really not so bad; neither are minor headaches. The 
fact is, as Donna Mildvan of Beth Israel said in a response to a question about AZT's toxicity, 
"AZT is not as toxic as AIDS". And there's nothing else yet available that addresses the virus 
itself successfully. Think about it. You can always go off AZT if you really feel you're 
suffering being on it. 
A couple of last comments. I agree fully with Michael Callen that no one should have to 
give up PCP prophylaxis to participate in a study. I came thrdugh my second bout of PCP eas-
ily enough, but I wasn't happy about it. For what it's worth, and without ui:g.ng "unethical" 
behavior, let me just say that the blood work done for the AZT study did not detect Bactrim. 
But it's a tricky game to play, trying to be on prophylaxis and stay in a study. We shouldn't 
have to make such a choice. 
~11-~~l\JJj~ 
SUBSCRIBE NOW TO THE AIDS PROJECT NEWSLETTER 
THIS NEWSIETTER RELIES TCYI'ALLY ON SUBSCRIPI'IONS TO EXIST. WE 
ARE GRATEFUL TO THOSE WHO HAVE SUBSCRIBED, AND TO THOSE WHO 
HAVE NCYI', PIEASE DO so NOW. s10.oo COVERS ONE YEAR (12 ISSUES). 
PIEASE MAKE YOUR CHECK OR MONEY ORDER PAY.ABLE TO "THE AIDS 
PROJECT". THANK YOU. 
---------------------------------------------------------------
*NOTE: The article on page 8 entitled "Some Thoughts On Aids Iss•.1es", was 
reprinted with permission from the PWA Coalition of New York City. 
CALENDAR 
JAN.15-17-Conference On Aids Ministry - Westin Oaks Galleria Hotel - Houston 
Texas - Designed by gay/lesbian people specifically for the gay/ 
lesbian community - Sponsored by Samaritan College and The UFMCC 
Board of Elders - Call 1-800-642-4386 for further information. 
JAN. 16 - "The Emotions of AIDS" - a one day workshop conducted by 
Jacob Watson , M.A. and Kristine Myers, M.A. - University of 
Southern Maine Portland - 9am - 4pm - contact Jacob at 761-2522 
or Kristine at 775-0366 for further information. 
JAN. 23 - The Merrymeeting Aids Support Services group will be conducting a 
"Buddy" training session - 9:00 am to 5:00 pm - location to be 
announced - call 729-8727 for further information. 
MAR.21-22-Interfaith Conference on AIDS and ARC - for detailed information 
contact: AIDS/ARC Conferenc~ Proceedings - c/o Shanti Project -
525 Howard Street - San Francisco, California 94105. 
SPRING 
1988 
- Aids Prevention Education Conference Follow-Up - Maine Medical 
Center - call 871-2131 for further information. 
JUL.20-26-The Second International Lesbian and Gay Health Conference and 
AIDS Forum - Call For Participation - Boston Park Plaza Hotel an~ 
Towers - To submit a proposal and for registration information 
contact NLGHF/AAPHR Programming Committee - P.O. Box 65472 -
Washington, D.C. 20035 or contact Michael Weeks at 202-797-3708 
or Greg Thomas at 202-994-4285, 
ONGOI'.'JG CALENDAR 
Every Tuesday from 10:30am to 12noon at The Aids Project - 48 Deering 
Street - Portland - there is a group meeting for all PWA's, PWArc, care-
givers, and family members, to share your thoughts and feelings relative 
to Aids. The meeting is conducted by Jacob Watson, M. A. Jacob is a 
psychotherapist specializing in loss and transition and is a staff member 
of the Elizabeth Kubler-Ross Center. 
Every Tuesday evening 7:00pm to 8:30pm at 29 Cushman Street - Portland -
there is a group meeting for all lovers, caregiv~rs, friends, and family 
members only. The meeting will be conducted by Brooke Alexander, an 
Episcopal priest and pastoral counselor. Call Brooke at 772-1678 or Lucy 
Marbach at The Aids Project 774-6877 for further information. 
Support Group for Parents of Adult Gay Children will meet the 2nd Tuesday 
of every month. Please call 774-HELP for time and place. 
Support group for Parents and Friends of Gays will meet the 4th Tuesday 
of every month at the Pilgrim House - 9 Cleaveland St. - Brunswick, Me. -
Call 729-9843 for further information . 
There is now an AIDS support group in the Bangor area meeting every Thurs-
day evening . Anyone interested in the group should call 469-7343 or write 
EMAN - P.O.Box 2038 - Bangor, Maine 04401 
WHEN YOU SEE SOMEONE WITHOUT A SMILE, 
GIVE THEM ONE OF YOURS ........ . 
TAP 
48 DEERING STREET 
PORTLAND, MAINE 04101 
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